Heart Outcomes Prevention Evaluation "HOPE"


Phase N/A Results


Patients receiving 10 mg ramipril had a significantly lower risk of stroke than those receiving placebo (3.4 percent vs. 4.9 percent; P < 0.001). Myocardial infarctions (P < 0.001), deaths from cardiovascular causes (P < 0.001), deaths from any cause (P = 0.005), revascularization procedures (P < 0.001), corrected heart failure (P < 0.001), and complications related to diabetes (P = 0.03) were also significantly reduced in the 10-mg ramipril group. 2.5 mg ramipril and Vitamin E prophylaxis showed no statistically significant benefits. Although there were no gender-based criteria for study involvement, the participants were 73% male.